Back to search

Article

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological Profiling

2024-06-19

Abstract excerpt

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) continues to be a global threat due to its ability to evolve and generate new subvariants, leading to new waves of infection. Additionally, other coronaviruses like Middle East respiratory syndrome coronavirus (MERS-CoV, formerly known as hCoV-EMC) which first emerged in 2012, persists and continues to present a threat of severe illness to humans. T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2ea345a0-e416-564b-9fbe-8c762a7bc7b4
DOI
10.20944/preprints202406.1311.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingDOI 10.20944/preprints202406.1311.v1
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected miceSemantic proximity
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacySemantic proximity
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity
Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical geneticsSemantic proximity
Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19Semantic proximity
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Semantic proximity
Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsSemantic proximity
Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus InfectionsSemantic proximity
Select a neighboring publication to make it the new centre.